Search Result
Results for "
β-agonist
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
4
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-117406
-
-
-
- HY-147055
-
-
-
- HY-136449
-
-
-
- HY-B1481B
-
Isoetarine hydrochloride
|
Others
|
Infection
|
Isoetharine hydrochloride is selective, short-acting and orally active β-agonist which is widely used as a bronchodilator in the research of inhalation research .
|
-
-
- HY-W742012
-
|
Isotope-Labeled Compounds
|
Others
|
Clencyclohexerol-d10 is the deuterium-labeled Clencyclohexerol (HY-117406). Clencyclohexerol-d10 is a β-agonist. Clencyclohexerol-d10 can be used as a growth promoter in animals .
|
-
-
- HY-153477
-
-
-
- HY-149218
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
Inflammation/Immunology
|
THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC50s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research .
|
-
-
- HY-160266
-
-
-
- HY-142917
-
|
Others
|
Metabolic Disease
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72) .
|
-
-
- HY-143613
-
|
Others
|
Metabolic Disease
|
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3) .
|
-
-
- HY-143614
-
|
Others
|
Metabolic Disease
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6) .
|
-
-
- HY-142441
-
|
Others
|
Endocrinology
|
THR-β Agonist 1 is a potent and selective agonist of THRβ. Thyroid hormone receptor mediates the physiological activity of thyroid hormones which plays a key role in normal growth and development of the body and in maintaining metabolic balance. THR-β Agonist 1 has the potential for the research of thyroid hormone receptor-related diseases (extracted from patent WO2021104288A1, compound 2) .
|
-
-
- HY-146275
-
|
LXR
|
Cancer
|
LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC50 of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC50 of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .
|
-
-
- HY-146997
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
TRβ agonist 1 is a selective and mutation-sensitive thyroid hormone receptor β (TRβ) agonist, with an EC50 value of 21 nM. TRβ agonist 1 can be used for researching dyslipidemia, nonalcoholic steatohepatitis (NASH), and resistance to thyroid hormone (RTH) .
|
-
-
- HY-147501
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
TRβ agonist 3 (Compound 3) is a potent agonist of TRβ. TRβ agonist 3 reduces lipid accumulation in HepG2 and promote lipolysis with comparable effects. TRβ agonist 3 is a new potential TRβ-selective thyromimetics .
|
-
-
- HY-147500
-
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
TRβ agonist 2 (Compound 1) is a potent agonist of TRβ. TRβ agonist 2 reduces lipid accumulation in HepG2 and promote lipolysis with comparable effects. TRβ agonist 2 is a new potential TRβ-selective thyromimetics .
|
-
-
- HY-152262
-
|
LXR
|
Inflammation/Immunology
|
LXRβ agonist-4 is a potent, orally active Liver X receptors (LXRs) agonist with an IC50 value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .
|
-
-
- HY-100469
-
|
LXR
|
Cardiovascular Disease
|
LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM, displays 28.5-fold selectivity over LXRα (EC50=200 nM) and used in the treatment of atherosclerosis .
|
-
-
- HY-19468
-
-
-
- HY-100327
-
-
-
- HY-101271
-
-
-
- HY-10629
-
WAY 252623
|
LXR
|
Metabolic Disease
Cancer
|
LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.
|
-
-
- HY-12216
-
-
-
- HY-149584
-
|
Estrogen Receptor/ERR
|
Cancer
|
CIDD-0149897 is a potent, selective and brain-penetrant ERβ agonist. CIDD-0149897 exert antitumor functions in glioblastoma .
|
-
-
- HY-16988
-
|
REV-ERB
|
Cancer
|
SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.
|
-
-
- HY-16988A
-
|
REV-ERB
|
Cancer
|
SR9011 hydrochloride is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively.
|
-
-
- HY-N0377
-
-
-
- HY-161253
-
|
Estrogen Receptor/ERR
|
Cancer
|
OSU-ERb-12 is a ERβ agonist, and suppress ovarian cancer cell proliferation in vitro and in vivo. OSU-ERb-12 decreases the expression of Snail .
|
-
-
- HY-18295
-
LY500307
|
Estrogen Receptor/ERR
|
Neurological Disease
|
Erteberel (LY500307) is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Erteberel has anti-tumor activities .
|
-
-
- HY-160207
-
-
-
- HY-A0070
-
Triiodothyronine sodium; 3,3',5-Triiodo-L-thyronine sodium; T3 sodium
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Endocrinology
Cancer
|
Liothyronine sodium is an active form of thyroid hormone. Liothyronine sodium is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-A0070A
-
-
-
- HY-A0070C
-
Triiodothyronine hydrochloride; 3,3',5-Triiodo-L-thyronine hydrochloride; T3 hydrochloride
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Endocrinology
Cancer
|
Liothyronine hydrochloride is an active form of thyroid hormone. Liothyronine hydrochloride is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-A0070B
-
Triiodothyronine sodium hydrate; 3,3',5-Triiodo-L-thyronine sodium hydrate; T3 sodium hydrate
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Endocrinology
Cancer
|
Liothyronine sodium hydrate is an active form of thyroid hormone. Liothyronine sodium hydrate is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-103446
-
-
-
- HY-119518
-
BMS-209641
|
RAR/RXR
|
Cancer
|
BMS641 (BMS-209641) is a selective RARβ agonist. BMS641 has a higher affinity for RARβ (Kd, 2.5 nM) that is 100 times higher than that for RARα (Kd, 225 nM) or RARγ (Kd, 223 nM) .
|
-
-
- HY-111288
-
-
-
- HY-100608
-
BMS453
1 Publications Verification
BMS-189453
|
|
|
BMS453 (BMS-189453), a synthetic retinoid, is a RARβ agonist and a RARα/RARγ antagonist. BMS453 inhibits breast cell growth predominantly through the induction of active TGFβ .
|
-
-
- HY-18295A
-
rel-LY500307
|
Estrogen Receptor/ERR
|
Neurological Disease
|
rel-Erteberel is rel isomer of Erteberel (HY-18295). Erteberel is a potent and selective estrogen receptor beta (ERβ) agonist with Ki and EC50 of 1.54 nM and 3.61 nM, respectively. Erteberel has anti-tumor activities .
|
-
-
- HY-15483
-
DY131
2 Publications Verification
GSK 9089
|
Estrogen Receptor/ERR
Smo
|
Endocrinology
Cancer
|
DY131 (GSK 9089) is a potent and selective ERRγ and ERRβ agonist. DY131displays inactive against ERRα, ERα and ERβ . DY131 also inhibits Smo signaling .
|
-
-
- HY-A0070AS2
-
Triiodothyronine-13C6-1; 3,3',5-Triiodo-L-thyronine-13C6-1; T3-13C6-1
|
Thyroid Hormone Receptor
|
Endocrinology
Cancer
|
Liothyronine-13C6-1 is a 13C-labeled Liothyronine. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-19383
-
PTP 112
|
|
|
Ertiprotafib is an inhibitor of PTP1B, IkB kinase β (IKK-β), and a dual PPARα and PPARβ agonist, with an IC50 of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC50 of ~1 μM for PPARα/PPARβ.
|
-
-
- HY-138690
-
|
Estrogen Receptor/ERR
|
Endocrinology
|
Estrogen receptor modulator 6 (compound 3a) is a selective estrogen receptor (ER) β agonist (Ki=0.44 nM). Estrogen receptor modulator 6 displays 19-fold selectivity for ERβ over ERα(Ki=8.4 nM) .
|
-
-
- HY-110157
-
|
Estrogen Receptor/ERR
|
Neurological Disease
|
AC-186 is a selective non-steroidal estrogen receptor β (ERβ) agonist with EC50s of 6 nM and 5000 nM for ERβ and ERα, respectively. AC-186 shows gender selective neuroprotective effects in a male rat model of Parkinson's disease .
|
-
-
- HY-A0070AR
-
Triiodothyronine (Standard); 3,3',5-Triiodo-L-thyronine (Standard); T3 (Standard)
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Cancer
|
Liothyronine (Standard) is the analytical standard of Liothyronine. This product is intended for research and analytical applications. Liothyronine is an active form of thyroid hormone. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-B0412
-
Estriol
3 Publications Verification
Oestriol
|
Estrogen Receptor/ERR
Endogenous Metabolite
|
Cancer
|
Estriol (Oestriol), an orally active estrogen, is a ERα and ERβ agonist. Estriol is a potent GPR30 antagonist in estrogen receptor-negative breast cancer cells. Estriol can ameliorate disease severity through immunomodulatory mechanisms that decrease tissue inflammation. Estriol has powerful proconvulsant effects .
|
-
-
- HY-A0070AG
-
Triiodothyronine; 3,3',5-Triiodo-L-thyronine; T3
|
Thyroid Hormone Receptor
|
Endocrinology
Cancer
|
Liothyronine (Triiodothyronine) (GMP) is Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-A0070AS1
-
Triiodothyronine-13C9,15N; 3,3',5-Triiodo-L-thyronine-13C9,15N; T3-13C9,15N
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
|
Liothyronine- 13C9, 15N is the 13C and 15N labeled Liothyronine[1]. Liothyronine is an active form of thyroid hormone. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[2][3][4].
|
-
-
- HY-D1734
-
|
LXR
|
Cardiovascular Disease
|
FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ .
|
-
-
- HY-123402
-
|
LXR
|
Metabolic Disease
|
GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation .
|
-
- HY-117167
-
|
Thyroid Hormone Receptor
|
Cancer
|
KB-141 is a potent and selective TRβ agonist. The IC50 values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .
|
-
- HY-14933
-
ERB-041
|
Estrogen Receptor/ERR
Wnt
Apoptosis
|
Cancer
|
Prinaberel (ERB-041) is a potent and selective estrogen receptor (ER) β agonist with IC50s of 5.4, 3.1 and 3.7 nM for human, rat and mouse ERβ, respectively. Prinaberel displays >200-fold selectivity for ERβ over ERα. Prinaberel is a potent skin cancer chemopreventive agent that acts by dampening the WNT/β-catenin signaling pathway. Prinaberel induces ovarian cancer apoptosis .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-A0070AG
-
Triiodothyronine (GMP); 3,3',5-Triiodo-L-thyronine (GMP); T3 (GMP)
|
Fluorescent Dye
|
Liothyronine (Triiodothyronine) (GMP) is Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
Cat. No. |
Product Name |
Type |
-
- HY-A0070AG
-
Triiodothyronine (GMP); 3,3',5-Triiodo-L-thyronine (GMP); T3 (GMP)
|
Biochemical Assay Reagents
|
Liothyronine (Triiodothyronine) (GMP) is Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W742012
-
|
Clencyclohexerol-d10 is the deuterium-labeled Clencyclohexerol (HY-117406). Clencyclohexerol-d10 is a β-agonist. Clencyclohexerol-d10 can be used as a growth promoter in animals .
|
-
-
- HY-160266
-
|
THR-β agonist-1 (Example 2) is a THR-β agonist, with EC50 values of 52 nM and 1017 nM for THR-β and THR-α, respectively .
|
-
-
- HY-A0070AS2
-
|
Liothyronine-13C6-1 is a 13C-labeled Liothyronine. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively .
|
-
-
- HY-A0070AS1
-
|
Liothyronine- 13C9, 15N is the 13C and 15N labeled Liothyronine[1]. Liothyronine is an active form of thyroid hormone. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with Kis of 2.33 nM for hTRα and hTRβ, respectively[2][3][4].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: